FLT3-ITD mutation

Clinico-hematological and molecular genetic variability of acute myeloid leukemia with CD7 expression on blasts cells

CLINICAL PRESENTATION, DIAGNOSIS, AND MANAGEMENT OF MYELOID MALIGNANCIES , , , ,

S.V. Gritsayev1, Z.V. Chubukina1, I.S. Martynkevich1, I.I. Kostroma1, T.V. Glazanova1, Ye.V. Petrova1, L.S. Martynenko1, S.A. Tiranova1, N.A. Potikhonova1, I.S. Zyuzgin2, L.N. Bubnova1, and K.M. Abdulkadyrov1

1 Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation

2 Leningrad Regional Hospital, Saint Petersburg, Russian Federation

ABSTRACT

The objective of the study was to evaluate the heterogeneity of patients with acute myeloid leukemia with CD7 aberrant expression. The retrospective analysis of 31 AML patients’ laboratory and clinical data was performed. Marked morphological, cytogenetic, and molecular heterogeneity of AML with CD7 coexpression was established. Also, it was found that these patients could be stratified into groups by overall survival. Four patients with t(8;21) or t(15;17) translocations or inv(16) inversion were followed-up for 53, 33, 11, and 10 months, respectively. The median of OS was not reached among the patients with t(8;21), t(15;15), and inv(16). The median OS among 10 patients with normal karyotype with no FLT3-ITD mutation was 17 months. The median OS among 17 patients with other genetic abnormalities including 7 patients with normal karyotype and FLT3-ITD mutation was 8 months; p = 0.033. We conclude that CD7 expression on AML blast cells is not an independent prognostic factor.

Keywords: acute myeloid leukemia, myeloblasts, CD7 coexpression, karyotype, FLT3-ITD mutation.

Read in PDF (RUS)pdficon

Referneces

  1. Vardiman J.W., Thiele J., Arber D.A. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2008; 114(5): 937–51.
  2. Dohner H., Estey T.Y., Amadori S. et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115(3): 453–74.
  3. Bene M.C., Castoldi G., Knapp W. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological characterization of Leukemias (EGIL). Leukemia 1995; 9(10): 1783–6.
  4. Macedo A., Orfao A., Vidriales M.D. et al. Characterization of aberrant phenotypes in acute myeloblastic leukemia. Ann. Hematol. 1995; 70(4): 189–94.
  5. Al-Mawali A., Gillis D., Lewis I. The role of multiparameter flow cytometry for detection of minimal residual disease in acute myeloid leukemia. Am. J. Clin. Pathol. 2009; 131(1): 16–26.
  6. Legrand O., Perrot J.Y., Baudard M. et al. The immunophenotype of 177 adults with acute myeloid leukemia: proposal of a prognostic score. Blood 2000; 96(3): 870–7.
  7. Bahia D.M., Yamamoto M., Chauffaille M.L. et al. Aberrant phenotypes I acute myeloid leukemia: a high frequency and its clinical significance. Haematologica 2001; 86(8): 801–6.
  8. Chang H., Salma F., Yi Q.L. et al. Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leuk. Res. 2004; 28(1): 43–8.
  9. Bene M.C. Immunophenotyping of acute leukaemias. Immunol. Lett. 2005; 98(1): 9–21.
  10. Plesa C., Chelghoum Y., Plesa A. et al. Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia. A single-institution experience. Cancer 2008; 112(3): 572–80.
  11. Bradstock K., Matthews J., Benson E. et al. Prognostic value of immunophenotyping in acute myeloid leukemia. Australian Leukaemia Study Group. Blood 1994; 84(4): 1220–5.
  12. Venditti A., Del Poeta G., Buccisano F. et al. Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia. Leukemia 1998; 12(7): 1056–63.
  13. Cruse J.M., Lewis R.E., Pierce S. et al. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp. Mol. Pathol. 2005; 79(1): 39–41.
  14. Lewis R.E., Cruse J.M., Sanders C.M. et al. Aberrant expression of T-cell markers in acute myeloid leukemia. Exp. Mol. Pathol. 2007; 83(3): 462–3.
  15. Chang H., Yeung J., Brandwein J., Yi Q-L. CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leuk. Res. 2007; 31(2): 157–62.
  16. Kita K., Miwa H., Nakase K. et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/ Lymphoma. Blood 1993; 81(9): 2399–405.
  17. Saxena A., Sheridan D.P., Card R.T. et al. Biologic and clinical significance of CD7 expression in acute myeloid leukemia. Am. J. Hematol. 1998; 58(4): 278–84.
  18. Ogata K., Yokose N., Shioi Y. et al. Reappraisal of the clinical significance of CD7 expression in association with cytogenetics in de novo acute myeloid leukaemia. Br. J. Haematol. 2001; 115(3): 612–5.
  19. Miwa H., Kita K., Nishii K. et al. Expression of MDR1 gene in acute leukemia cells: association with CD7+ acute myeloblastic leukemia/acute lymphoblastic leukemia. Blood 1993; 82(11): 3445–51.
  20. Eto T.A., Harada K., Shibuya M. et al. Biological characteristics of CD7 positive acute myelogenous leukemia. Br. J. Haematol. 1992; 82(3): 508–14.
  21. Shimamoto T., Ohyashiki J.H., Ohyashiki K. et al. Clinical and biologic characteristics of CD7+ acute myeloid leukemia. Our experience and literature review. Cancer Genet. Cytogen. 1994; 73(1): 69–74.
  22. Dang H., Jiang A., Kamel-Reid S. et al. Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Hum. Pathol. 2013; 44(1): 55–61.
  23. Li X., Li J., Du D. et al. Relevance of immunophenotypes to prognostic subgroups of age, WBC, platelet count, and cytogenetics in de novo acute myeloid leukemia. APMIS 2010; 119(1): 76–84.
  24. Мартынкевич И.С., Грицаев С.В., Москаленко М.В. и др. Мутации генов FLT3 и NPM1 у больных острыми миелоидными лейкозами и влияние мутации FLT3-ITD на выживаемость больных с нормальным кариотипом. Тер. арх. 2010; 12: 33–9.  [Martynkevich I.S., Gritsayev S.V., Moskalenko M.V. i dr. Mutatsii genov FLT3 i NPM1 u bolnykh ostrymi miyeloidnymi leykozami i vliyaniye mutatsii FLT3-ITD na vyzhivayemost bolnykh s normalnym kariotipom (FLT3 and NPM1 gene mutations in patients with acute myeloid leukemias and impact of FLT3-ITD mutations on survival of patients with normal karyotype. In: Ther. archive). Ter. arkh. 2010; 12: 33–9.]
  25. Cheson B.D., Bennett J.M., Kopecky K.J. et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J. Clin. Oncol. 2003; 21(24): 4642–9.
  26. Zhao X.F., Gojo I., York T. et al. Diagnosis of biphenotypic acute leukemia: a paradigmatic approach. Int. J. Clin. Exp. Pathol. 2009; 3(1): 75–86.
  27. Xu X.Q., Wang J.M., Lu S.Q. et al. Clinical and biological characteristics of adult biphenotypic acute leukemia in comparison with that of acute myeloid leukemia and acute lymphoblastic leukemia: a case series of a Chinese population. Haematologica 2009; 94(7): 919–27.
  28. Baer M.R., Stewart C.C., Lawrence D. et al. Expression of the neural cell adhesion molecular CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(821)(q22q22). Blood 1997; 90(4): 1643–8.
  29. Murray C.K., Estey E., Paietta E. et al. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome? J. Clin. Oncol. 1999; 17(1): 293–7.
  30. Raspadori D., Damiani D., Lenoci M. et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia 2001; 15(8): 1161–4.
  31. Arber D.A., Jenkins K.A., Slovak M.L. CD79a expression in acute myeloid leukemia. High frequency of expression in acute promyelocytic leukemia. Am. J. Pathol. 1996; 149(4): 1105–10.
  32. Tiacci E., Pileri S., Orleth A. et al. PAX5 expression in acute leukemias: higher B-lineage specificity than CD79a and selective association with t(8;21)- acute myelogenous leukemia. Cancer Res. 2004; 64(20): 7399–404.
  33. Kozlov I., Beason K., Yu C., Hughson M. CD79a expression in acute myeloid leukemia t(8;21) and the importance of cytogenetics in the diagnosis of leukemias with immunophenotypic ambiguity. Cancer Genet. Cytogenet. 2005; 163(1): 62–7.
  34. Rabinowich H., Pricop L., Herberman R.B., Whiteside L. Expression and function of CD7 molecule on human natural killer cells. J. Immunol. 1994; 152(2): 517–26.
  35. Barcena A., Muench M.O., Roncarolo M.G., Spits H. Tracing the expression of CD7 and other antigens during T- and myeloid-cell differentiation in the human fetal liver and thymus. Leuk. Lymphoma 1995; 17(1–2): 1–11.
  36. Sempowski G.D., Lee D.M.N., Kaufman R.E., Hanes B.F. Structure and function of the CD7 molecule. Crit. Rev. Immunol. 1999; 19(4): 331–48.
  37. Del Poeta G., Stasi R., Aronica G. et al. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87(5): 1997–2001.
  38. Грицаев С.В., Мартынкевич И.С., Мартыненко Л.С. и др. Сравни- тельный анализ кариотипа пожилых больных с миелодиспластическим син- дромом и острым миелоидным лейкозом. Клин. онкогематол. 2010; 2: 114–8. [Gritsayev S.V., Martynkevich I.S., Martynenko L.S. i dr. Sravnitelnyy analiz kariotipa pozhilykh bolnykh s miyelodisplasticheskim sindromom i ostrym miyeloidnym leykozom (Comparative analysis of karyotype in patients with myelodisplastic syndrome and acute myeloid leukemia. In: Clin. oncohematol.). Klin. onkogematol. 2010; 2: 114–8.]
  39. Грицаев С.В., Мартынкевич И.С., Абдулкадыров К.М. и др. Воз- растные особенности кариотипа больных острым миелоидным лейкозом. Тер. арх. 2011; 1: 51–5. [Gritsayev S.V., Martynkevich I.S., Abdulkadyrov K.M. i dr. Vozrastnye osobennosti kariotipa bolnykh ostrym miyeloidnym leykozom (Age-related characteristics of karyotype in patients with acute myeloid leukemia. In: Ther. archive). Ter. arkh. 2011; 1: 51–5.]
  40. Грицаев С.В., Мартынкевич И.С., Мартыненко Л.С. и др. Возраст и кариотип — факторы риска у больных первичным острым миелоидным лейкозом. Клин. онкогематол. 2010; 4: 359–64. [Gritsayev S.V., Martynkevich I.S., Martynenko L.S. i dr. Vozrast i kariotip — faktory riska u bolnykh pervichnym ostrym miyeloidnym leykozom (Age and karyotype as risk factors in patients with primary acute myeloid leukemia. In: Clin. oncohematol.). Klin. onkogematol. 2010; 4: 359–64]
  41. Rausei-Mills V., Chang K.L., Gaal K.K. et al. Aberrant expression of CD7 in myeloblasts is highly associated with de novo acute myeloid leukemias with FLT3/ITD mutation. Am. J. Clin. Pathol. 2008; 129(4): 624–9.
  42. Chauhan P.S., Bhushan B., Mishra A.K. et al. Mutation of FLT3 gene in acute myeloid leukemia with normal cytogenetics and its association with clinical and immunophenotypic features. Med. Oncol. 2011; 28(2): 544–51.
  43. Грицаев С.В., Мартынкевич И.С., Петрова Е.В. и др. Выживаемость больных CBF вариантами de novo острого миелоидного лейкоза (ОМЛ) и кариотип. Вестн. гематол. 2012; 4: 11. [Gritsayev S.V., Martynkevich I.S., Petrova Ye.V. i dr. Vyzhivayemost bolnykh CBF variantami de novo ostrogo miyeloidnogo leykoza (OML) i kariotip (Survival of patients with de novo CBF variants of acute myeloid leukemias (OML) and karyotype. In: Bull. of hematol.). Vestn. gematol. 2012; 4: 11]
  44. Dalal B.I., Mansoor S., Manna M. et al. Detection of CD34, TdT, CD56, CD2, CD4, and CD14 by flow cytometry is associated with NPM1 and FLT3 mutation status in cytogenetically normal acute myeloid leukemia. Clin. Lymph. Myel. Leuk. 2012; 12(4): 274–9.
  45. Chen M.H., Atenafu E., Craddock K.J. et al. CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. Leuk. Res. 2013; 37(2): 122–8.